Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents [note 7] $ 16,664 $ 9,515
Short-term investments [note 7]   5,089
Amounts receivable 8 7
Prepaid expenses 662 926
Total current assets 17,334 15,537
Restricted cash [note 7] 50 50
Property and equipment, net [note 8] 57 35
Right-of-use assets [note 13] 329  
Other assets [note 9] 187 118
License agreement [note 2, 5 and 6] 2,087 2,310
Goodwill [note 2] 1,034 1,034
Total assets 21,078 19,084
Current liabilities:    
Accounts payable 859 144
Accrued liabilities other 304 748
Accrued clinical liabilities 387 1,199
Accrued compensation 1,116 1,168
Current portion of long-term obligations [note 13] 203 11
Total current liabilities 2,869 3,270
Long-term obligations [note 13] 159 12
Total liabilities 3,028 3,282
Commitments and contingencies [note 13]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 29,485,178 and 6,721,117 issued and outstanding at December 31, 2019 and December 31, 2018, respectively. 41 18
Additional paid-in capital 63,709 41,161
Accumulated deficit (45,704) (25,381)
Accumulated other comprehensive income 4 4
Total stockholders' equity 18,050 15,802
Total liabilities and stockholders' equity 21,078 19,084
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value